{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:24:24Z","timestamp":1787495064645,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Research Grants Council of the Hong Kong","award":["14109516"],"award-info":[{"award-number":["14109516"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472339"],"award-info":[{"award-number":["81472339"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11154-021-09684-8","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T09:08:52Z","timestamp":1630400932000},"page":"421-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The emerging role of transcription factor FOXP3 in thyroid cancer"],"prefix":"10.1007","volume":"23","author":[{"given":"Zhongqin","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingbin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongcai","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhai","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C. F.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"9684_CR1","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388:2783\u201395.","journal-title":"The Lancet"},{"key":"9684_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jpedsurg.2018.10.010","volume":"54","author":"JC Rubinstein","year":"2019","unstructured":"Rubinstein JC, Dinauer C, Herrick-Reynolds K, Morotti R, Callender GG, Christison-Lagay ER. Lymph node ratio predicts recurrence in pediatric papillary thyroid cancer. J Pediatr Surg. 2019;54:129\u201332.","journal-title":"J Pediatr Surg"},{"key":"9684_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11864-020-00776-2","volume":"21","author":"W Alobuia","year":"2020","unstructured":"Alobuia W, Gillis A, Kebebew E. Contemporary management of anaplastic thyroid cancer. Curr Treat Options Oncol. 2020;21:78.","journal-title":"Curr Treat Options Oncol"},{"key":"9684_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.clon.2017.02.009","volume":"29","author":"L Valerio","year":"2017","unstructured":"Valerio L, Pieruzzi L, Giani C, Agate L, Bottici V, Lorusso L, et al. Targeted therapy in thyroid cancer: state of the art. Clin Oncol (R Coll Radiol). 2017;29:316\u201324.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"9684_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-018-0786-0","volume":"17","author":"GE Naoum","year":"2018","unstructured":"Naoum GE, Morkos M, Kim B, Arafat W. Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol Cancer. 2018;17:51.","journal-title":"Mol Cancer"},{"key":"9684_CR6","doi-asserted-by":"crossref","unstructured":"Laetitia G, Sven S, Fabrice J. Combinatorial therapies in thyroid cancer: an overview of preclinical and clinical progresses. Cells. 2020;9.","DOI":"10.3390\/cells9040830"},{"key":"9684_CR7","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40:1573\u2013604.","journal-title":"Endocr Rev"},{"key":"9684_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621\u201330.","journal-title":"N Engl J Med"},{"key":"9684_CR9","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2147\/CMAR.S191499","volume":"11","author":"ST Yu","year":"2019","unstructured":"Yu ST, Ge JN, Luo JY, Wei ZG, Sun BH, Lei ST. Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis. Cancer Manag Res. 2019;11:1525\u201332.","journal-title":"Cancer Manag Res"},{"key":"9684_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/joim.12470","volume":"279","author":"S Muenst","year":"2016","unstructured":"Muenst S, Laubli H, Soysal SD, Zippelius A, Tzankov A, Hoeller S. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med. 2016;279:541\u201362.","journal-title":"J Intern Med"},{"key":"9684_CR11","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","volume":"10","author":"Y Wu","year":"2019","unstructured":"Wu Y, Chen W, Xu ZP, Gu W. PD-L1 Distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022.","journal-title":"Front Immunol"},{"key":"9684_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12022-020-09630-5","volume":"31","author":"I Girolami","year":"2020","unstructured":"Girolami I, Pantanowitz L, Mete O, Brunelli M, Marletta S, Colato C, et al. Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma. Endocr Pathol. 2020;31:291\u2013300.","journal-title":"Endocr Pathol"},{"key":"9684_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","volume":"19","author":"SM Ferrari","year":"2018","unstructured":"Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord. 2018;19:325\u201333.","journal-title":"Rev Endocr Metab Disord"},{"key":"9684_CR14","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1210\/jc.2009-2564","volume":"95","author":"JD French","year":"2010","unstructured":"French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2325\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"9684_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12020-012-9853-2","volume":"44","author":"H Yu","year":"2013","unstructured":"Yu H, Huang X, Liu X, Jin H, Zhang G, Zhang Q, et al. Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter. Endocrine. 2013;44:172\u201381.","journal-title":"Endocrine"},{"key":"9684_CR16","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1089\/thy.2013.0423","volume":"24","author":"HS Ryu","year":"2014","unstructured":"Ryu HS, Park YS, Park HJ, Chung YR, Yom CK, Ahn SH, et al. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma. Thyroid. 2014;24:1232\u201340.","journal-title":"Thyroid"},{"key":"9684_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/thy.2012.0589","volume":"24","author":"C Ugolini","year":"2014","unstructured":"Ugolini C, Elisei R, Proietti A, Pelliccioni S, Lupi C, Borrelli N, et al. FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to iodine 131 treatment. Thyroid. 2014;24:339\u201346.","journal-title":"Thyroid"},{"key":"9684_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev-immunol-100219-020937","volume":"38","author":"PA Savage","year":"2020","unstructured":"Savage PA, Klawon DEJ, Miller CH. Regulatory T Cell Development. Annu Rev Immunol. 2020;38:421\u201353.","journal-title":"Annu Rev Immunol"},{"key":"9684_CR19","doi-asserted-by":"crossref","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330\u201336.","DOI":"10.1038\/ni904"},{"key":"9684_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/cei.13357","volume":"199","author":"G Deng","year":"2020","unstructured":"Deng G, Song X, Greene MI. FoxP3 in Treg cell biology: a molecular and structural perspective. Clin Exp Immunol. 2020;199:255\u201362.","journal-title":"Clin Exp Immunol"},{"key":"9684_CR21","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/ni.2402","volume":"13","author":"D Rudra","year":"2012","unstructured":"Rudra D, deRoos P, Chaudhry A, Niec RE, Arvey A, Samstein RM, et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol. 2012;13:1010\u20139.","journal-title":"Nat Immunol"},{"key":"9684_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2006.05.042","volume":"126","author":"Y Wu","year":"2006","unstructured":"Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006;126:375\u201387.","journal-title":"Cell"},{"key":"9684_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.it.2007.06.006","volume":"28","author":"H Hu","year":"2007","unstructured":"Hu H, Djuretic I, Sundrud MS, Rao A. Transcriptional partners in regulatory T cells: Foxp3. Runx and NFAT Trends Immunol. 2007;28:329\u201332.","journal-title":"Runx and NFAT. Trends Immunol"},{"key":"9684_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.immuni.2011.08.012","volume":"35","author":"Y Wang","year":"2011","unstructured":"Wang Y, Su MA, Wan YY. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity. 2011;35:337\u201348.","journal-title":"Immunity"},{"key":"9684_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41590-018-0291-z","volume":"20","author":"C Konopacki","year":"2019","unstructured":"Konopacki C, Pritykin Y, Rubtsov Y, Leslie CS, Rudensky AY. Transcription factor Foxp1 regulates Foxp3 chromatin binding and coordinates regulatory T cell function. Nat Immunol. 2019;20:232\u201342.","journal-title":"Nat Immunol"},{"key":"9684_CR26","doi-asserted-by":"crossref","unstructured":"Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 Control over Foxp3+ Regulatory T Cell Function. Science. 2008;322:271\u201374.","DOI":"10.1126\/science.1160062"},{"key":"9684_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/ni1549","volume":"9","author":"Y Tone","year":"2008","unstructured":"Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol. 2008;9:194\u2013202.","journal-title":"Nat Immunol"},{"key":"9684_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1677\/erc.1.0978","volume":"12","author":"M Xing","year":"2005","unstructured":"Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245\u201362.","journal-title":"Endocr Relat Cancer"},{"key":"9684_CR29","doi-asserted-by":"crossref","unstructured":"Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg.\u00a02007;246:466-70; discussion 470\u201361.","DOI":"10.1097\/SLA.0b013e318148563d"},{"key":"9684_CR30","doi-asserted-by":"publisher","first-page":"932","DOI":"10.7150\/jca.33105","volume":"11","author":"J Ge","year":"2020","unstructured":"Ge J, Wang J, Wang H, Jiang X, Liao Q, Gong Q, et al. The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer. J Cancer. 2020;11:932\u20139.","journal-title":"Journal of Cancer"},{"key":"9684_CR31","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/sj.bjc.6605277","volume":"101","author":"RJ Flockhart","year":"2009","unstructured":"Flockhart RJ, Armstrong JL, Reynolds NJ, Lovat PE. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Br J Cancer. 2009;101:1448\u201355.","journal-title":"Br J Cancer"},{"key":"9684_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nri2489","volume":"9","author":"A Collins","year":"2009","unstructured":"Collins A, Littman DR, Taniuchi I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nat Rev Immunol. 2009;9:106\u201315.","journal-title":"Nat Rev Immunol"},{"key":"9684_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature05673","volume":"446","author":"M Ono","year":"2007","unstructured":"Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, et al. Foxp3 controls regulatory T-cell function by interacting with AML1\/Runx1. Nature. 2007;446:685\u20139.","journal-title":"Nature"},{"key":"9684_CR34","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1084\/jem.20090226","volume":"206","author":"L Bruno","year":"2009","unstructured":"Bruno L, Mazzarella L, Hoogenkamp M, Hertweck A, Cobb BS, Sauer S, et al. Runx proteins regulate Foxp3 expression. J Exp Med. 2009;206:2329\u201337.","journal-title":"The Journal of Experimental Medicine"},{"key":"9684_CR35","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/ni.1795","volume":"10","author":"D Rudra","year":"2009","unstructured":"Rudra D, Egawa T, Chong MM, Treuting P, Littman DR, Rudensky AY. Runx-CBFbeta complexes control expression of the transcription factor Foxp3 in regulatory T cells. Nat Immunol. 2009;10:1170\u20137.","journal-title":"Nat Immunol"},{"key":"9684_CR36","doi-asserted-by":"publisher","first-page":"E1249","DOI":"10.1210\/jc.2011-2624","volume":"97","author":"L Dalle Carbonare","year":"2012","unstructured":"Dalle Carbonare L, Frigo A, Francia G, Davi MV, Donatelli L, Stranieri C, et al. Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer. J Clin Endocrinol Metab. 2012;97:E1249-1256.","journal-title":"J Clin Endocrinol Metab"},{"key":"9684_CR37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/labinvest.2012.84","volume":"92","author":"DF Niu","year":"2012","unstructured":"Niu DF, Kondo T, Nakazawa T, Oishi N, Kawasaki T, Mochizuki K, et al. Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. Lab Invest. 2012;92:1181\u201390.","journal-title":"Lab Invest"},{"key":"9684_CR38","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1210\/en.2015-2046","volume":"157","author":"FE Carr","year":"2016","unstructured":"Carr FE, Tai PW, Barnum MS, Gillis NE, Evans KG, Taber TH, et al. Thyroid Hormone Receptor-beta (TRbeta) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer. Endocrinology. 2016;157:3278\u201392.","journal-title":"Endocrinology"},{"key":"9684_CR39","doi-asserted-by":"crossref","unstructured":"Ren J, Han L, Tang J, Liu Y, Deng X, Liu Q,\u00a0et al. Foxp1 is critical for the maintenance of regulatory T-cell homeostasis and suppressive function. PLoS Biol. 2019;17:e3000270.","DOI":"10.1371\/journal.pbio.3000270"},{"key":"9684_CR40","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1007\/s12032-012-0288-7","volume":"29","author":"W Jiang","year":"2012","unstructured":"Jiang W, Li L, Tang Y, Zhang WY, Liu WP, Li GD. Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients. Med Oncol. 2012;29:3352\u20139.","journal-title":"Med Oncol"},{"key":"9684_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.immuni.2010.09.001","volume":"33","author":"L Xu","year":"2010","unstructured":"Xu L, Kitani A, Stuelten C, McGrady G, Fuss I, Strober W. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity. 2010;33:313\u201325.","journal-title":"Immunity"},{"key":"9684_CR42","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1084\/jem.20112646","volume":"209","author":"SM Schlenner","year":"2012","unstructured":"Schlenner SM, Weigmann B, Ruan Q, Chen Y, von Boehmer H. Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut. J Exp Med. 2012;209:1529\u201335.","journal-title":"J Exp Med"},{"key":"9684_CR43","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/onc.2016.233","volume":"36","author":"A Garcia-Rendueles","year":"2017","unstructured":"Garcia-Rendueles A, Rodrigues J, Garcia-Rendueles M, Suarez-Fari\u00f1a M, Perez-Romero S, Barreiro F, et al. Rewiring of the apoptotic TGF-\u03b2-SMAD\/NF\u03baB pathway through an oncogenic function of p27 in human papillary thyroid cancer. Oncogene. 2017;36:652\u201366.","journal-title":"Oncogene"},{"key":"9684_CR44","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.4049\/jimmunol.1100179","volume":"186","author":"S Horiuchi","year":"2011","unstructured":"Horiuchi S, Onodera A, Hosokawa H, Watanabe Y, Tanaka T, Sugano S, et al. Genome-wide analysis reveals unique regulation of transcription of Th2-specific genes by GATA3. J Immunol. 2011;186:6378\u201389.","journal-title":"The Journal of Immunology"},{"key":"9684_CR45","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3389\/fimmu.2018.00530","volume":"9","author":"RKW Mailer","year":"2018","unstructured":"Mailer RKW. Alternative splicing of FOXP3-Virtue and vice. Front Immunol. 2018;9:530.","journal-title":"Front Immunol"},{"key":"9684_CR46","doi-asserted-by":"crossref","unstructured":"Van Gool F, Nguyen MLT, Mumbach MR, Satpathy AT, Rosenthal WL, Giacometti S, et al. A mutation in the transcription factor Foxp3 drives T helper 2 effector function in regulatory T cells. Immunity. 2019;50:362\u201377;e366.","DOI":"10.1016\/j.immuni.2018.12.016"},{"key":"9684_CR47","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.3389\/fimmu.2019.02486","volume":"10","author":"G Deng","year":"2019","unstructured":"Deng G, Song X, Fujimoto S, Piccirillo CA, Nagai Y, Greene MI. Foxp3 post-translational modifications and Treg suppressive activity. Front Immunol. 2019;10:2486.","journal-title":"Front Immunol"},{"key":"9684_CR48","doi-asserted-by":"crossref","unstructured":"Jia H, Qi H, Gong Z, Yang S, Ren J, Liu Y,\u00a0et al. The expression of FOXP3 and its role in human cancers. Biochim Biophys Acta (BBA) Rev Cancer.\u00a02019;1871:170\u201378.","DOI":"10.1016\/j.bbcan.2018.12.004"},{"key":"9684_CR49","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/eji.200737590","volume":"38","author":"T Aarts-Riemens","year":"2008","unstructured":"Aarts-Riemens T, Emmelot ME, Verdonck LF, Mutis T. Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells. Eur J Immunol. 2008;38:1381\u201390.","journal-title":"Eur J Immunol"},{"key":"9684_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jaut.2015.06.009","volume":"63","author":"AL Joly","year":"2015","unstructured":"Joly AL, Liu S, Dahlberg CI, Mailer RK, Westerberg LS, Andersson J. Foxp3 lacking exons 2 and 7 is unable to confer suppressive ability to regulatory T cells in vivo. J Autoimmun. 2015;63:23\u201330.","journal-title":"Journal of Autoimmunity"},{"key":"9684_CR51","doi-asserted-by":"publisher","first-page":"10235","DOI":"10.1074\/jbc.RA117.001349","volume":"293","author":"J Du","year":"2018","unstructured":"Du J, Wang Q, Ziegler SF, Zhou B. FOXP3 interacts with hnRNPF to modulate pre-mRNA alternative splicing. J Biol Chem. 2018;293:10235\u201344.","journal-title":"J Biol Chem"},{"key":"9684_CR52","doi-asserted-by":"crossref","first-page":"89017","DOI":"10.1155\/2007\/89017","volume":"2007","author":"HJ van der Vliet","year":"2007","unstructured":"van der Vliet HJ, Nieuwenhuis EE. IPEX as a result of mutations in FOXP3. Clin Dev Immunol. 2007;2007:89017.","journal-title":"Clinical and Developmental Immunology"},{"key":"9684_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fped.2019.00020","volume":"7","author":"C Agakidis","year":"2019","unstructured":"Agakidis C, Agakidou E, Sarafidis K, Papoulidis I, Xinias I, Farmaki E. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome associated with a novel mutation of FOXP3 gene. Front Pediatr. 2019;7:20.","journal-title":"Front Pediatr"},{"key":"9684_CR54","doi-asserted-by":"crossref","unstructured":"Hayatsu N, Miyao T, Tachibana M, Murakami R, Kimura A, Kato T,\u00a0et al. Analyses of a mutant Foxp3 allele reveal BATF as a critical transcription factor in the differentiation and accumulation of tissue regulatory T cells. Immunity. 2017;47:268\u201383:e269.","DOI":"10.1016\/j.immuni.2017.07.008"},{"key":"9684_CR55","doi-asserted-by":"crossref","unstructured":"Zhao Y, Guo H, Qiao G, Zucker M, Langdon WY, Zhang J. E3 ubiquitin ligase Cbl-b regulates thymic-derived CD4+CD25+ regulatory T cell development by targeting Foxp3 for ubiquitination. J Immunol (Baltimore, Md : 1950).\u00a02015;194:1639\u201345.","DOI":"10.4049\/jimmunol.1402434"},{"key":"9684_CR56","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/nm.3085","volume":"19","author":"H Nie","year":"2013","unstructured":"Nie H, Zheng Y, Li R, Guo TB, He D, Fang L, et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med. 2013;19:322\u20138.","journal-title":"Nat Med"},{"key":"9684_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2018.09.011","volume":"97","author":"Y Kagoya","year":"2019","unstructured":"Kagoya Y, Saijo H, Matsunaga Y, Guo T, Saso K, Anczurowski M, et al. Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells. J Autoimmun. 2019;97:10\u201321.","journal-title":"J Autoimmun"},{"key":"9684_CR58","doi-asserted-by":"crossref","unstructured":"Lei Zheng WJ, Yang Zhang LX. Association between FOXP3, FOXE1 Gene polymorphisms and risk of differentiated thyroid cancer in Chinese han population. Mol Biol. 2015;04.","DOI":"10.4172\/2168-9547.1000131"},{"key":"9684_CR59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3109\/15513815.2013.864347","volume":"33","author":"L Szylberg","year":"2014","unstructured":"Szylberg L, Bodnar M, Harasymczuk J, Marszalek A. Expression of FoxP3 protein plays a key role in thyroid tumors in children. Fetal Pediatr Pathol. 2014;33:84\u201391.","journal-title":"Fetal Pediatr Pathol"},{"key":"9684_CR60","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.mce.2014.10.006","volume":"399","author":"R Chu","year":"2015","unstructured":"Chu R, Liu SY, Vlantis AC, van Hasselt CA, Ng EK, Fan MD, et al. Inhibition of Foxp3 in cancer cells induces apoptosis of thyroid cancer cells. Mol Cell Endocrinol. 2015;399:228\u201334.","journal-title":"Mol Cell Endocrinol"},{"key":"9684_CR61","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.ymthe.2018.06.015","volume":"26","author":"S Wang","year":"2018","unstructured":"Wang S, Wu J, Ren J, Vlantis AC, Li MY, Liu SYW, et al. MicroRNA-125b interacts with Foxp3 to induce autophagy in thyroid cancer. Mol Ther. 2018;26:2295\u2013303.","journal-title":"Mol Ther"},{"key":"9684_CR62","doi-asserted-by":"crossref","unstructured":"Amin D, Richa T, Mollaee M, Zhan T, Tassone P, Johnson J,\u00a0et al. Metformin effects on FOXP3(+) and CD8(+) T cell infiltrates of head and neck squamous cell carcinoma. Laryngoscope. 2019.","DOI":"10.1002\/lary.28336"},{"key":"9684_CR63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/OTT.S227915","volume":"13","author":"Y He","year":"2020","unstructured":"He Y, Cao L, Wang L, Liu L, Huang Y, Gong X. Metformin inhibits proliferation of human thyroid cancer TPC-1 cells by decreasing LRP2 to suppress the JNK pathway. Onco Targets Ther. 2020;13:45\u201350.","journal-title":"OncoTargets and therapy"},{"key":"9684_CR64","doi-asserted-by":"crossref","unstructured":"Casares N, Rudilla F, Arribillaga L, Llopiz D, Riezu-Boj JI, Lozano T,\u00a0et al. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol (Baltimore, Md : 1950).\u00a02010;185:5150\u201359.","DOI":"10.4049\/jimmunol.1001114"},{"key":"9684_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.biomaterials.2016.03.007","volume":"91","author":"T Lozano","year":"2016","unstructured":"Lozano T, Soldevilla MM, Casares N, Villanueva H, Bendandi M, Lasarte JJ, et al. Targeting inhibition of Foxp3 by a CD28 2\u2019-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. Biomaterials. 2016;91:73\u201380.","journal-title":"Biomaterials"},{"key":"9684_CR66","doi-asserted-by":"crossref","unstructured":"Qiu H, Zhang J, Guo Q, Zhang Y, Zhong X. Prunella vulgaris L. attenuates experimental autoimmune thyroiditis by inducing indoleamine 2,3-dioxygenase 1 expression and regulatory T cell expansion. Biomed Pharmacother.\u00a02020;128:110288.","DOI":"10.1016\/j.biopha.2020.110288"},{"key":"9684_CR67","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.4049\/jimmunol.1502352","volume":"196","author":"V Sasidharan Nair","year":"2016","unstructured":"Sasidharan Nair V, Song MH, Oh KI. Vitamin C facilitates demethylation of the Foxp3 enhancer in a Tet-dependent manner. J Immunol. 2016;196:2119\u201331.","journal-title":"The Journal of Immunology"},{"key":"9684_CR68","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3389\/fimmu.2019.01772","volume":"10","author":"MT Cantorna","year":"2019","unstructured":"Cantorna MT, Lin YD, Arora J, Bora S, Tian Y, Nichols RG, et al. Vitamin D regulates the microbiota to control the numbers of ROR\u03b3t\/FoxP3+ regulatory T cells in the colon. Front Immunol. 2019;10:1772.","journal-title":"Front Immunol"},{"key":"9684_CR69","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.7150\/thno.35219","volume":"9","author":"X Su","year":"2019","unstructured":"Su X, Shen Z, Yang Q, Sui F, Pu J, Ma J, et al. Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK\/ERK and PI3K\/AKT pathways via distinct mechanisms. Theranostics. 2019;9:4461\u201373.","journal-title":"Theranostics"},{"key":"9684_CR70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/bs.apcsb.2019.11.010","volume":"121","author":"J Huang","year":"2020","unstructured":"Huang J, Wang S, Jia Y, Zhang Y, Dai X, Li B. Targeting FOXP3 complex ensemble in drug discovery. Adv Protein Chem Struct Biol. 2020;121:143\u201368.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"9684_CR71","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.bcp.2013.03.013","volume":"85","author":"R Mao","year":"2013","unstructured":"Mao R, Xiao W, Liu H, Chen B, Yi B, Kraj P, et al. Systematic evaluation of 640 FDA drugs for their effect on CD4(+)Foxp3(+) regulatory T cells using a novel cell-based high throughput screening assay. Biochem Pharmacol. 2013;85:1513\u201324.","journal-title":"Biochem Pharmacol"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-021-09684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-021-09684-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-021-09684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T21:18:21Z","timestamp":1699391901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-021-09684-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["9684"],"URL":"https:\/\/doi.org\/10.1007\/s11154-021-09684-8","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"24 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}